



# EFSA's Role in Nutrition & Health Claims

- **EU Regulation on nutrition and health claims**
- **EFSA review of the evidence for scientific substantiation of health claims**
- **Status of applications, ongoing and near future**

# REGULATION (EC) No 1924/2006

of 20 December 2006

on nutrition and health claims made on foods



- **Types of health claims:**
  - function claims
  - disease risk reduction claims
  - claims on development and health of children
- Applies equally to supplements, ingredients, other foods
- No provision for qualified health claims or different standards for different foods
  - ➔ A single standard of evidence for substantiation
- **Nutrition claims**

- All claims must be authorised and all must be assessed by EFSA (*“on the highest possible standard”*, recital 23) before authorisation
- All claims must be substantiated by generally accepted scientific evidence
  - = generally accepted by scientific experts
- Taking into account totality of available scientific data, and weighing the evidence

# Types of Health Claims

## ‘Function claims’

**Art.13.1**

Generally accepted scientific evidence



**Art.13.5**

Newly developed scientific data/  
proprietary data

Reduction of disease risk

**Art. 14.1(a)**



Risk factor  
e.g.  
LDL cholesterol




Children’s development and health


**Art. 14.1(b)**



# Process for “General Function Claims” Art 13.1



# Art 13.1 Claims received by EFSA





# Process for Art 14 Claims (new science, children, risk reduction)

- **Validation of application**
  - Submission to Member State: admissibility check; if ok, sent to EFSA
  - EFSA checks completeness; if ok, clock starts
- **EFSA evaluation**
  - Evaluation and adoption of opinion within 5 months; in case additional information is needed, the evaluation time is extended (clock stop time plus 1 or 2 months)
  - Pre-notification of applicant
  - Publication of opinion, informing EC and Member States
- **EC takes decision through regulatory procedure with scrutiny**
  - 30 days for public to comment on opinion to EC
  - EFSA to respond on scientific comments received

= claim which states or suggests that a food has particular beneficial nutritional properties due to the content of energy, nutrient(s) or other substances

Art 8: only be permitted if they are listed in the Annex and are in conformity with this Regulation.



Art 28: Nutrition claims which are not included in the Annex shall be communicated by MS to the EC (31 Jan 08). EC/MS to decide. (EFSA consultation if appropriate).



1. Characterisation of food/substance
2. Beneficial to human health
3. Cause and effect relationship
4. Food quantity required for claimed effect
5. Representativeness of data for target population

# 1. Characterisation




*Valeriana  
officinalis*



Essential for the assessors and for the regulators

## 2. Beneficial Effect

- Is the claimed effect beneficial for human health?
  - Validity of end-point used
  - Size of effect
  - Benefit in EU population groups



# 3. Cause and Effect Relationship

- Is a cause and effect relationship established between the consumption of the food/constituent and the claimed effect in humans?
- Characteristics of the food-health relationship
  - strength
  - consistency
  - specificity
  - dose-response
  - biological plausibility, mechanistic studies

# 4. Food Quantity

- Is the quantity of food/constituent proposed for the claimed effect adequate? (*dose tested vs dose proposed*)
- Could the quantity of the food/constituent and pattern of consumption required to obtain the claimed effect reasonably be consumed as part of a balanced diet?

# 5. Representative Study Population

- Is the specific study group(s) in which the evidence was obtained representative of the target population for which the claim is intended?
  - Patients vs. healthy subjects?
  - Obese vs. normal weight?
  - Adults vs. children?
  - Case-by-case judgement





- a. Selection & review of relevant human studies
- b. Review of studies on biological plausibility - mechanisms, bioavailability
- c. Weighing the evidence - combining the relevant human studies + other studies to conclude on substantiation

- studies carried out with the food/constituent for claim
- appropriate outcome measure(s) for the claimed effect
- conditions for studies comparable to conditions of use for claim (e.g. quantity of food/constituent)
- study groups representative of the target group or extrapolation to the target population possible

- Published and unpublished studies accepted
- Review by study type – e.g. intervention, observational
- Study quality – design, execution, analysis, reporting
- Additional information may be requested from the applicant
- Studies of low quality may be excluded

- combine the relevant human studies by study type (RCT strongest evidence): number of studies for and against, taking into account study population, study quality, study size, effect size, dose-response, consistency among studies
  - evidence for biological plausibility – bioavailability, mechanisms; studies in humans, animals, *in vitro*
  - no pre-established formula (number/type of studies)  
*case by case judgement by NDA Panel experts*
- **Transparent description in the published opinion**

# EFSA Health Claims Evaluation Status

12/10/2012

Claim type	Received	Withdrawn	Adopted	In progress	Under Validation
Children (Art. 14)	220	110	53 op. covering 60 applications	1*	49
Disease risk reduction (Art. 14)	58	23	32 op. covering 33 applications	0**	2
New science/ proprietary (Art. 13.5)	107	18	65 op. covering 66 applications	19***	4
Conditions of use (Art. 19)	2	0	2	0	0
<b>Total applications</b>	<b>387</b>	<b>151</b>	<b>152</b> opinions covering 161 applications	<b>20</b>	<b>55</b>
<b>Art 13 list of health claims</b>	<b>4728<sup>#</sup></b>	<b>331</b>	<b>2849<sup>#</sup></b> (2849 published)	<b>0</b>	<b>1548</b> (on hold)

<sup>#</sup> 4730 & 2851 questions in RAW because of 2 duplicated items

\* 0 in clock stop \*\* 0 in clock stop \*\*\* 11 in clock stop

- **EFSA guidance:**
  - preparation and presentation of applications (2007)
  - general principles for substantiation of claims (2009, 2010)
  - scientific requirements for substantiation of specific types of health claims (2010-2012)
- **EFSA dialogue with applicants** before acceptance and during evaluation, clock stops, EFSA's response to comments after publication
- **Stakeholder meetings** to discuss general principles and specific topics, Scientific colloquium
- **Presentations at conferences**

- EFSA committed to maintain the quality and timeliness of the applications
- EFSA to further assist applicants by providing additional guidance and through ongoing dialogue with applicants and other stakeholders
- Web-consultations and where appropriate scientific meetings during 2012 and 2013
- Establishment of “Application Helpdesk”
- EFSA awaits regulatory decision on „botanicals“



# THANK YOU



Committed *since 2002*  
to ensuring that Europe's food is safe